Review of NICE Technology Appraisal Guidance No.191; Capecitabine for treating advanced gastric cancer

Proposal to move guidance to the static list

The planned date for review of the above guidance is May 2013.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is no new evidence available that would lead to a change in the recommendation in TA191.  The price of Capecitabine is largely unchanged and there are likely to be generic formulations available in the near future. Consequently we propose that the original guidance should be transferred to the static list.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted. 

May 2013